AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27348904 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint embedding therapy applied to Ganshu (BL 18), Tai‐chong (LR 3), Fenglong (ST 40), Zusanli (ST 36), and Sanyinjiao (SP 6), once every 7 days for 6 months.
Number of subjects: 180
Study 27348904 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint embedding therapy group
Number of subjects: 180
Study 27348904 — intervention group
Group type: COMPARATOR
Intervention: Polyene phosphatidylcholine capsules (essentiale), 228 mg/capsule, 2 capsules three times a day for 6 months.
Number of subjects: 180
Study 25089880 — intervention group
Group type: EXPERIMENTAL
Intervention: AP-training group (action preferences training)
Number of subjects: 2
Study 25089880 — intervention group
Group type: COMPARATOR
Intervention: NP-training group (no action preferences training)
Number of subjects: 2
Study 22914550 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase advanced misalignment (3 × 21 h)
Number of subjects: 13
Study 22914550 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase delayed misalignment (3 × 27 h)
Number of subjects: 13
Study 20159428 — intervention group
Group type: COMPARATOR
Intervention: Topiramate 100 mg/day
Number of subjects: 0
Study 20159428 — intervention group
Group type: COMPARATOR
Intervention: Topiramate 50 mg/day
Number of subjects: 0
Study 17950182 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial massage (20 min)
Number of subjects: 6
Study 17950182 — intervention group
Group type: COMPARATOR
Intervention: Foot massage (20 min)
Number of subjects: 6
Study 15019896 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated pulse pressure (PP)
Number of subjects: 489
Study 15019896 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pulse pressure (PP)
Number of subjects: 489
Study 11799759 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole‐trimethoprim (SXT) prophylaxis
Number of subjects: 0
Study 11799759 — intervention group
Group type: COMPARATOR
Intervention: Nontyphoidal salmonellae sensitivity
Number of subjects: 0
Study 11799759 — intervention group
Group type: COMPARATOR
Intervention: Shigellae sensitivity
Number of subjects: 0
Study 9923576 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive formulation containing 2 mg dienogest and 0.03 mg ethinylestradiol (group A)
Number of subjects: 23
Study 9923576 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive formulation containing 0.125 mg levonorgestrel and 0.03 mg ethinylestradiol (group B)
Number of subjects: 23
Study 7848003 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 168
Study 3140134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin alone (9 subjects)
Number of subjects: 28
Study 3140134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin and prednisolone (10 subjects)
Number of subjects: 28
Study 3140134 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine and prednisolone (9 subjects)
Number of subjects: 28
Study 3140134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin and prednisolone (6 subjects, measured at 2 years)
Number of subjects: 28
Study 3140134 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine and prednisolone (6 subjects, measured at 2 years)
Number of subjects: 28
Study 1095133 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg/day
Number of subjects: 20
Study 1095133 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin soluble 4 g/day
Number of subjects: 20
Study 1095133 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin and aspirin taken together
Number of subjects: 20
Study 30646167 — intervention group
Group type: EXPERIMENTAL
Intervention: Head CT Choice decision aid
Number of subjects: 971
Study 30646167 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 971
Study 30646167 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 971
Study 27401083 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia
Number of subjects: 60
Study 27401083 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 60
Study 24342115 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy (eight-week body-mind-spirit group psychotherapy)
Number of subjects: 71
Study 24342115 — intervention group
Group type: COMPARATOR
Intervention: Control (one-session psychoeducation)
Number of subjects: 71
Study 23341786 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive chemoradiotherapy (CRT)
Number of subjects: 124
Study 23341786 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy (SRT)
Number of subjects: 124
Study 20389106 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (fat content: 38 g, energy content: 640 kcal)
Number of subjects: 7
Study 20389106 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meal (fat content: 2 g, energy content: 320 kcal)
Number of subjects: 7
Study 20389106 — intervention group
Group type: EXPERIMENTAL
Intervention: Both meals
Number of subjects: 7
Study 20389106 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 7
Study 18480831 — intervention group
Group type: EXPERIMENTAL
Intervention: Central augmentation index (CAI%)
Number of subjects: 143
Study 18480831 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic strain (AoS)
Number of subjects: 143
Study 18480831 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds ratio (OR) of AoS for diastolic dysfunction
Number of subjects: 143
Study 18480831 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds ratio (OR) of CAI for diastolic dysfunction
Number of subjects: 143
Study 18480831 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of CAI to multivariable model
Number of subjects: 143
Study 16145341 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG) at 10 to 10 cfu/day
Number of subjects: 0
Study 16145341 — intervention group
Group type: COMPARATOR
Intervention: Control (unsupplemented formula)
Number of subjects: 0
Study 14700092 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypermetropic group
Number of subjects: 131
Study 14700092 — intervention group
Group type: EXPERIMENTAL
Intervention: Low myopic group
Number of subjects: 131
Study 14700092 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium myopic group
Number of subjects: 131
Study 14700092 — intervention group
Group type: EXPERIMENTAL
Intervention: High myopic group
Number of subjects: 131
Study 10772429 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg qd x 5 d)
Number of subjects: 30
Study 10772429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8882668 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar macrophages from AIDS patients
Number of subjects: 0
Study 8882668 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS patients with Pneumocystis carinii infection
Number of subjects: 0
Study 8882668 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 2059758 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell depletion
Number of subjects: 48
Study 2059758 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin and methotrexate (CSA + MTX)
Number of subjects: 48
Study 6851564 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO 802 pessaries (1 mg of 16, 16-dimethyl-trans-delta 2-prostaglandin E1 methyl ester)
Number of subjects: 195
Study 6851564 — intervention group
Group type: COMPARATOR
Intervention: Placebo pessaries (no treatment)
Number of subjects: 195
Study 6851564 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO 802 pessaries
Number of subjects: 195
Study 6851564 — intervention group
Group type: COMPARATOR
Intervention: Placebo pessaries
Number of subjects: 195
Study 30144521 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose Accelerated (HDA) Vaccination
Number of subjects: 0
Study 30144521 — intervention group
Group type: COMPARATOR
Intervention: Standard Dose (SD) Vaccination
Number of subjects: 0
Study 28229275 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Treatment Group (hyaluronic acid-based vaginal moisturizer)
Number of subjects: 57
Study 28229275 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Treatment Group (prebiotic vaginal moisturizer)
Number of subjects: 57
Study 28229275 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Group-H
Number of subjects: 57
Study 28229275 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group
Number of subjects: 57
Study 24754682 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 30
Study 24754682 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 30
Study 22417647 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-performed joint counts by patients
Number of subjects: 0
Study 22417647 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-performed joint counts in patients in remission (SDAI ≤ 3.3)
Number of subjects: 0
Study 22417647 — intervention group
Group type: COMPARATOR
Intervention: Separate training session for patients
Number of subjects: 0
Study 20962623 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day (started 3 days before coronary angiography)
Number of subjects: 240
Study 20962623 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic statin therapy
Number of subjects: 240
Study 20962623 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 240
Study 17396251 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg/day for 14 days (group A1)
Number of subjects: 113
Study 17396251 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/day for 14 days (group A2)
Number of subjects: 113
Study 17396251 — intervention group
Group type: COMPARATOR
Intervention: Control group (B1 and B2) receiving only pain-relieving therapy
Number of subjects: 113
Study 16223069 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity comprehensive behavioral treatment based on motivational interviewing and Cognitive Behavioral Therapy
Number of subjects: 0
Study 16223069 — intervention group
Group type: COMPARATOR
Intervention: Standardized abstinence-oriented treatment
Number of subjects: 0
Study 12150228 — intervention group
Group type: EXPERIMENTAL
Intervention: Just deserts perspective
Number of subjects: 1016
Study 12150228 — intervention group
Group type: EXPERIMENTAL
Intervention: Deterrence perspective
Number of subjects: 1016
Study 12150228 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed model confirmed through structural equation modeling (SEM)
Number of subjects: 1016
Study 12150228 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual sentencing decisions
Number of subjects: 1016
Study 9702644 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone therapy (0.2 U/kg subcutaneously daily for 28 days)
Number of subjects: 10
Study 9702644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7617248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (average daily dose of 4 g in half of the cases and 6 g in the others, average treatment period of 8 days)
Number of subjects: 25
Study 7617248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 25
Study 3567124 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol (1.5 mg/kg)
Number of subjects: 32
Study 3567124 — intervention group
Group type: COMPARATOR
Intervention: Pethidine (1.5 mg/kg)
Number of subjects: 32
Study 29203068 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-minute riboflavin dosing interval
Number of subjects: 510
Study 29203068 — intervention group
Group type: COMPARATOR
Intervention: 5-minute riboflavin dosing interval
Number of subjects: 510
Study 29203068 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosing intervals
Number of subjects: 510
Study 27483127 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 11
Study 27483127 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 11
Study 25196117 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued glucocorticoid use
Number of subjects: 2485
Study 25196117 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoid withdrawal
Number of subjects: 2485
Study 22695185 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb-761 (Ginkgo biloba) 240 mg per day for 12 weeks
Number of subjects: 368
Study 22695185 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 368
Study 20521321 — intervention group
Group type: EXPERIMENTAL
Intervention: water plus 75 mg of caffeine and 75 g of glucose
Number of subjects: 72
Study 20521321 — intervention group
Group type: EXPERIMENTAL
Intervention: water plus 75 mg of caffeine
Number of subjects: 72
Study 20521321 — intervention group
Group type: EXPERIMENTAL
Intervention: water plus 75 g of glucose
Number of subjects: 72
Study 20521321 — intervention group
Group type: COMPARATOR
Intervention: water (150 ml)
Number of subjects: 72
Study 18954244 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 0
Study 18954244 — intervention group
Group type: EXPERIMENTAL
Intervention: Videophone follow-up
Number of subjects: 0
Study 18954244 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 18954244 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (telephone, videophone, usual care)
Number of subjects: 0
Study 19826418 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFIRI.3
Number of subjects: 61
Study 19826418 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX
Number of subjects: 61
Study 15761605 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (300 microg/kg body weight at a single dose, repeated after 24 h)
Number of subjects: 54
Study 15761605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 11726264 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject A (male weight-trained, age 21)
Number of subjects: 19
Study 11726264 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 similarly trained men, age 24.7)
Number of subjects: 19
Study 9239586 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol Patient-Controlled Sedation (PCS) - 0.5 mg/kg, lockout interval 3 min
Number of subjects: 19
Study 9239586 — intervention group
Group type: COMPARATOR
Intervention: Anesthesiologist-administered midazolam-fentanyl sedation
Number of subjects: 19
Study 8307806 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment team (n = 33)
Number of subjects: 69
Study 8307806 — intervention group
Group type: COMPARATOR
Intervention: Standard care (nonteam, n = 36)
Number of subjects: 69
Study 3326677 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 200 mg
Number of subjects: 327
Study 3326677 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 100 mg
Number of subjects: 327
Study 3326677 — intervention group
Group type: COMPARATOR
Intervention: Codeine 60 mg
Number of subjects: 327
Study 3326677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study 11421505 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler (MDI) with terbutaline 1.5 mg (six puffs) and ipratropium 120 microg (six puffs) via two inspirations to total lung capacity and a 10-sec breath-hold per puff
Number of subjects: 20
Study 11421505 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler (MDI) with terbutaline 1.5 mg (six puffs) and ipratropium 120 microg (six puffs) via six tidal breaths
Number of subjects: 20
Study 11421505 — intervention group
Group type: COMPARATOR
Intervention: Nebulized terbutaline 5 mg and ipratropium 500 microg
Number of subjects: 20
Study 31294598 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjoint behavioral consultation (CBC) intervention
Number of subjects: 267
Study 31294598 — intervention group
Group type: COMPARATOR
Intervention: Control group (business as usual)
Number of subjects: 267
Study 30132426 — intervention group
Group type: EXPERIMENTAL
Intervention: SAM treatment plus flocculent/disinfectant water treatment
Number of subjects: 901
Study 30132426 — intervention group
Group type: EXPERIMENTAL
Intervention: SAM treatment plus chlorine disinfectant
Number of subjects: 901
Study 30132426 — intervention group
Group type: EXPERIMENTAL
Intervention: SAM treatment plus ceramic water filter
Number of subjects: 901
Study 30132426 — intervention group
Group type: COMPARATOR
Intervention: Standard SAM treatment
Number of subjects: 901
Study 27459527 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (Group A)
Number of subjects: 198
Study 27459527 — intervention group
Group type: COMPARATOR
Intervention: Untreated euthyroid thyroid antibody positive women (Group B)
Number of subjects: 198
Study 27459527 — intervention group
Group type: COMPARATOR
Intervention: Untreated thyroid antibody negative women (Group C)
Number of subjects: 198
Study 25224315 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication Quality Assurance intervention (report card)
Number of subjects: 92
Study 25224315 — intervention group
Group type: COMPARATOR
Intervention: Control group (no report card)
Number of subjects: 92
Study 22617015 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine granules 1.5 g once-daily
Number of subjects: 487
Study 22617015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study 20429742 — intervention group
Group type: EXPERIMENTAL
Intervention: Corset treatment (A)
Number of subjects: 91
Study 20429742 — intervention group
Group type: COMPARATOR
Intervention: No corset treatment (B)
Number of subjects: 91
Study 20429742 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low calorie diet (VLCD)
Number of subjects: 91
Study 17267922 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs approved by the EMEA for psychiatric disorders
Number of subjects: 0
Study 15177518 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 12
Study 15177518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12095067 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐aminolevulinic acid (ALA) with photodynamic therapy (PDT)
Number of subjects: 0
Study 9828754 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention programme
Number of subjects: 104
Study 7863823 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term rhGH treatment (1 week)
Number of subjects: 8
Study 7863823 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained rhGH treatment (5 weeks)
Number of subjects: 8
Study 2692402 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 45
Study 2692402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 30974993 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbinator wand
Number of subjects: 150
Study 30974993 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflex Ultra wand
Number of subjects: 150
Study 28007634 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention including culturally tailored interactive multimedia component and counseling sessions
Number of subjects: 0
Study 28007634 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 25201887 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fish oil (3 capsules/day, 1080 mg eicosapentaenoic acid + docosahexaenoic acid)
Number of subjects: 24
Study 25201887 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fish oil
Number of subjects: 24
Study 25201887 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fish oil
Number of subjects: 24
Study 25201887 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil, linoleic acid)
Number of subjects: 24
Study 23375618 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 589
Study 23375618 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 589
Study 22012640 — intervention group
Group type: EXPERIMENTAL
Intervention: vMLSS (13.56±0.90 km·h‐1)
Number of subjects: 8
Study 22012640 — intervention group
Group type: COMPARATOR
Intervention: v5×2000 (12.93±0.90 km·h‐1)
Number of subjects: 8
Study 22012640 — intervention group
Group type: EXPERIMENTAL
Intervention: Tlim at vMLSS (64±15 min)
Number of subjects: 8
Study 22012640 — intervention group
Group type: COMPARATOR
Intervention: Tlim at v5×2000 (94±21 min)
Number of subjects: 8
Study 17362279 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride 25 mg taken 1-2 hours before sexual activity for 8 weeks
Number of subjects: 60
Study 17362279 — intervention group
Group type: COMPARATOR
Intervention: Placebo taken 1-2 hours before sexual activity for 8 weeks
Number of subjects: 60
Study 17062648 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab + methotrexate
Number of subjects: 161
Study 17062648 — intervention group
Group type: COMPARATOR
Intervention: Placebo + methotrexate
Number of subjects: 161
Study 17062648 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab alone
Number of subjects: 161
Study 17062648 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab + cyclophosphamide
Number of subjects: 161
Study 12855215 — intervention group
Group type: EXPERIMENTAL
Intervention: Health educator-led classroom program
Number of subjects: 0
Study 12855215 — intervention group
Group type: COMPARATOR
Intervention: Self-instruction classroom program
Number of subjects: 0
Study 12855215 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study 10493673 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating thrombopoietin (TPO) concentrations in SSc
Number of subjects: 13
Study 10493673 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 13
Study 10493673 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with rheumatoid arthritis (RA)
Number of subjects: 13
Study 8757423 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin pastilles (200,000 U)
Number of subjects: 128
Study 8757423 — intervention group
Group type: COMPARATOR
Intervention: Placebo pastilles
Number of subjects: 128
Study 1683811 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 27
Study 1683811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 7075121 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of naproxen daily
Number of subjects: 24